Adult Dosing

Diagnostic aid

• Single-dose short test
• 30 mg/kg PO at midnight with yogurt or milk
• Max: 3 g

• Multiple-dose test
• 750 mg PO q4 hrs for 6 doses

Pediatric Dosing

Diagnostic aid

• Single-dose short test
• 30 mg/kg PO at midnight with yogurt or milk
• Max: 3 g
• Multiple-dose test
• 15 mg/kg PO q4 hrs for 6 doses; use a minimal single dose of 250 mg

[Outline]

• Adult Dosing
• Pediatric Dosing

• Used as a diagnostic drug for testing hypothalamic-pituitary ACTH function

• Hypersensitivity to any of the ingredients of the product
• Adrenal cortical insufficiency

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Acute adrenal insufficiency has been reported when used in patients with reduced adrenal secretory capacity. Hence do not use in patients with adrenocortical insufficiency
• In patients with hypo- or hyperthyroidism subnormal response to the metyrapone test may occur
• Before employing metyrapone test, confirm the ability of adrenals to respond to exogenous ACTH
• Metyrapone can cause dizziness and sedation, caution the patient to avoid operating machinery or driving vehicle

Cautions: Use cautiously in

• Hypothyroidism
• Hyperthyroidism
• Elderly

Pregnancy Category:C

Breastfeeding: Unlikely to affect a breastfed infant because few amounts of drug and its metabolite appears in milk, this can be further minimized by avoiding nursing for 2 to 2.5 hours after each dose. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 21 April 2011). Manufacturer advises caution.

• CNS: Headache, dizziness, sedation
• CV: Hypotension
• GI: Nausea, vomiting, abdominal discomfort or pain
• DERM: Allergic rash
• HEMA: Decreased white blood cell count, bone marrow depression

• Diagnostic agent; reduces cortisol and corticosterone production, inhibits the 11-ß-hydroxylation reaction in the adrenal cortex
• Metabolized in liver and kidney
• Excreted in urine: 5.3% (unchanged) and 38.5%(metabolite)
• Half-life: 1.9 +/- 0.7 hrs

US Trade Name(s)

• Metopirone

US Availability

Metopirone

• CAPS: 250 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Metopirone

UK Availability

Metopirone

• CAPS: 250 mg

Australian Trade Name(s)

• Metopirone

Australian Availability

Metopirone

• CAPS: 250 mg

[Outline]

Endocrine/Metabolic

Diagnostic Agents

Drug Name: Metopirone 250 MG Oral Capsule

Ingredient(s): Metyrapone

Imprint: CIBA;LN

Color(s): White

Shape: Capsule

Size (mm): 19.00

Score: 1

Inactive Ingredient(s): 4-methoxyacetophenone / brown ink / ethyl vanillin / gelatin / glycerine / polyethylene glycol / sodium ethyl hydroxybenzoate / sodium propyl hydroxybenzoate / titanium dioxide

Drug Label Author:
Novartis Pharmaceuticals Corporation

DEA Schedule:
Non-Scheduled